

IN THE CLAIMS:

Claims 1-20. (Cancelled).

Claim 21. (New) A binding compound comprising an antigen binding site of an antibody that specifically binds to SEQ ID NOs:2 or 4.

Claim 22. (New) The binding compound of Claim 21 that is:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody;
- d) an Fv, Fab, or F(ab')₂ fragment;
- e) glycosylated;
- f) attached to a carrier or a solid substrate; or
- g) detectably labeled.

Claim 23. (New) A binding composition comprising the binding compound of Claim 21, and a carrier, wherein the carrier is:

- a) an aqueous compound, including water, saline, or buffer; or
- b) formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

Claim 24. (New) A kit comprising the binding compound of Claim 21 and:

- a) a compartment;
- b) instructions for use; or
- c) a source of the polypeptide of SEQ ID NOs:2 or 4.

Claim 25. (New) A method of making the binding compound of Claim 21, comprising immunizing with an immunogenic amount of the polypeptide of SEQ ID NOs:2 or 4, or an antigenic fragment thereof.

Claim 26. (New) The method of Claim 25, wherein the antigenic fragment comprises:

- a) amino acids 5-11; 9-20; 15-20; 24-30; 30-41; 45-50; 49-60; 58-64; 63-74; 69-74; 76-81; 76-87; 91-96; 92-103; 99-105; 107-113; 118-124; 127-138; 131-136; 139-146; 141-152; 154-160; 156-167; 163-169; 175-180; 179-190; 185-190; 193-204; 201-207; or 205-216; of SEQ ID NO:2; or
- b) amino acids 30-41; 45-50; 49-60; 107-113; 156-167; or 163-169; of SEQ ID NO:4.

Claim 27. (New) A method of producing an antigen:antibody complex, comprising contacting the polypeptide of SEQ ID NOs:2 or 4 with the antibody of Claim 22, thereby allowing the complex to form.

Claim 28. (New) A method of modulating a cell involved in an inflammatory response comprising contacting the cell with:

- a) an agonist of SEQ ID NOs:2 or 4; or
- b) an antagonist of SEQ ID NOs:2 or 4.

Claim 29. (New) The method of Claim 28, wherein:

- a) the agonist comprises SEQ ID NOs:2 or 4; or
- b) the antagonist comprises an antigen binding site of an antibody that specifically binds to SEQ ID NOs:2 or 4.

Claim 30. (New) The method of Claim 28, wherein:

- a) the cell is a fibroblast or keratinocyte; or
- b) the response is psoriasis.

Claim 31. (New) A method of treating a subject suffering from an inflammatory response or immunological disorder comprising administering an effective amount of:

- a) an agonist of SEQ ID NOs:2 or 4; or
- b) an antagonist of SEQ ID NOs:2 or 4.

Claim 32. (New) The method of Claim 31, wherein:

- a) the agonist comprises SEQ ID NOs:2 or 4; or
- b) the antagonist comprises an antigen binding site of an antibody that specifically binds to SEQ ID NOs:2 or 4.

Claim 33. (New) The method of Claim 31, wherein the response or disorder comprises:

- a) fibroblast or keratinocyte response; or
- b) psoriasis.